drugset / Trial / NCT06285422
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
NaSingle-groupOpen-labelTreatment
Summary
SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Timeline
- Start
- 2024-04-18
- Primary completion
- 2025-12
- Completion
- 2029-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |